A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death. An updated analysis of patients in the SPARTAN ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

Prostate cancer remains one of the most common cancers among men with an estimated 1.5 million cases diagnosed worldwide. While hormone therapy has long been the cornerstone of treatment for ...

At a median follow-up of 21.5 months, ADT plus apalutamide significantly prolonged median PSA progression-free survival compared with ADT monotherapy (24.9 vs 20.3 months; hazard ratio [HR], 0.52).

Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA ® reduced risk of death by 23 percent at 24 months compared to enzalutamide LISBON, Portugal, Oct. 2, 2024 /PRNewswire/ -- ...

Among prostate cancer patients with a luminal B subtype, the 5-year biochemical progression-free survival rate was 72% in the apalutamide group and 54% in the placebo group. Recurrent prostate cancer ...

The next-generation oral antiandrogen product apalutamide (Erleada, Janssen), is approaching approval in Europe for use in nonmetastatic castration-resistant prostate cancer (nmCRPC). The product ...

Interim safety analysis of a randomized phase II trial comparing pembrolizumab with radiation versus pembrolizumab, olaparib, and radiation in localized high risk prostate cancer. This is an ASCO ...

The advent of more effective treatment combinations for metastatic hormone-sensitive prostate cancer (mHSPC) has been built on successes in therapy development for metastatic, castration-resistant ...